DOSEF.US Doseology Sciences Inc.
- Market cap
- USD 779K
- P/E
- -
- P/B
- 1.00x
- ROE
- -112.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Mar 2026.
Is DOSEF.US undervalued?
Graham numberThe Graham number of Doseology Sciences Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Doseology Sciences Inc. fundamental analysis
No fundamental analysis for Doseology Sciences Inc. yet.
Doseology Sciences Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Doseology Sciences Inc.
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., develops, manufactures, and sells nutritional wellness products in Canada. The company offers oral stimulants, medicinal mushroom products, tinctures, and brain-focused nutritional and wellness products. The company sells its products online and offline. Doseology Sciences Inc. was formerly known as Pcybin Therapeutic Inc. and changed its name to Doseology Sciences Inc. in January 2020. The company was incorpor…
Full company profileDoseology Sciences Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Doseology Sciences Inc. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 16.0K | 43.1K | 98.5K | 42.6K | 107K |
| Gross Profit | - | 0.00 | -148K | 41.3K | 72.1K | 18.9K | 26.7K |
| Operating Income | -432K | -1.56M | -1.81M | -767K | -378K | -472K | -1.26M |
| EBITDA | - | -1.47M | -1.67M | -701K | -357K | -472K | -1.26M |
| Net Income | -432K | -1.63M | -1.94M | -1.78M | -340K | -448K | -1.24M |
| EPS | -0.11 | -0.04 | -0.05 | -0.04 | -0.08 | -0.06 | -0.15 |
| Balance Sheet | |||||||
| Total Assets | 1.16M | 5.99M | 3.87M | 1.40M | 1.10M | 1.49M | 1.18M |
| Total Liabilities | 88.1K | 3.41M | 872K | 99.2K | 82.5K | 94.1K | 80.9K |
| Shareholders' Equity | 1.07M | 2.58M | 3.00M | 1.30M | 1.02M | 1.40M | 1.10M |
| Cash & Short-term Investments | 341K | 3.73M | 1.87M | 1.30M | 1.06M | 1.43M | 367K |
| Total Debt | - | 688K | 746K | 50.3K | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -129K | -2.37M | -1.71M | -481K | -235K | -342K | -1.42M |
| Capital Expenditure | 0.00 | 170K | 7.88K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -129K | -2.54M | -1.72M | -481K | -235K | -342K | -1.42M |
| Ratios | |||||||
| ROE | -40.3% | -63.1% | -64.7% | -137.1% | -33.3% | -32.0% | -112.6% |
| ROA | -37.2% | -27.2% | -50.1% | -127.4% | -30.8% | -30.0% | -104.9% |
| Net Profit Margin | - | - | -12,084.5% | -4,134.7% | -344.9% | -1,052.2% | -1,160.0% |
| Debt to Equity | - | 0.27x | 0.25x | 0.04x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Doseology Sciences Inc. dividends
Doseology Sciences Inc. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:10 on Feb 16, 2024.
Who owns Doseology Sciences Inc.
- Insiders 23.27%
- Institutions 0.00%
- Public & others 76.73%
- Shares outstanding 8.09M
Doseology Sciences Inc. company profile
- Company name
- Doseology Sciences Inc.
- Ticker
- DOSEF.US
- ISIN
- CA2584842033
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 9-3151 Lakeshore Road, Kelowna, BC, Canada, V1W 3S9
- Phone
- 604-908-3095
- Website
- doseology.com
About Doseology Sciences Inc.
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., develops, manufactures, and sells nutritional wellness products in Canada. The company offers oral stimulants, medicinal mushroom products, tinctures, and brain-focused nutritional and wellness products. The company sells its products online and offline. Doseology Sciences Inc. was formerly known as Pcybin Therapeutic Inc. and changed its name to Doseology Sciences Inc. in January 2020. The company was incorporated in 2019 and is based in Kelowna, British Columbia, Canada.
Doseology Sciences Inc. management
3- Mr. Daniel ViceCo-Founder
- Mr. Kareem BaalbakiInterim CEO, Interim CFO & Director
- Ms. Lindsay HamelinCorporate Secretary